

Special Issue

Epigenetic Signatures in Metabolic Health and Cancer

Message from the Guest Editor

This Special Issue focuses on the epigenetic signatures associated with metabolic health and cancer. These epigenetic signatures are potential companion diagnostic biomarkers, which can aid in the prediction of disease risk or cancer prognosis. We invite articles related to epigenetics in the subject area of diabetes research, obesity, cardiovascular diseases, and various types of cancer. Articles related to gene–environment interaction and cancer disease risk prediction will be considered. Understanding and elucidating the molecular signatures and pathways associated with metabolic health recovery and cancer diagnosis/prognosis would be the key purpose of this Special Issue.

Guest Editor

Dr. Aparna Duggirala

Biomedical and Clinical Science Research Theme, School of Science,
University of Derby, Derby DE22 1GB, UK

Deadline for manuscript submissions

30 April 2026



Epigenomes

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 4.4
Indexed in PubMed



mdpi.com/si/250733

Epigenomes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
epigenomes@mdpi.com

[mdpi.com/journal/
epigenomes](https://mdpi.com/journal/epigenomes)





Epigenomes

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 4.4
Indexed in PubMed



[mdpi.com/journal/
epigenomes](https://mdpi.com/journal/epigenomes)



About the Journal

Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

Epigenomes (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Editor-in-Chief

Prof. Dr. Ernesto Guccione

Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, NY 10029, USA

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, PubAg, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Biochemistry, Genetics and Molecular Biology (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).